公开(公告)号：KR1020090084557A

公开(公告)日：2009-08-05

申请号：KR1020080010808

申请日：2008-02-01

Applicant: 전남대학교병원

Inventor： 김태성 ,  김형준 ,  조원제

IPC: A61K31/19 ,  A61K31/47 ,  A61K31/472 ,  A61P35/00

Abstract: A therapeutic agent of leukemia is provided to safely treat leukemia by parallelly using an all-trans retinoic acid(ATRA) and indeno[1,2-c] isoquinoline derivative. An anticancer drug comprises all-trans retinoic acid and indeno[1,2-c]isoquinoline derivative of the general formula (I) as an active ingredient and pharmaceutically allowable carrier. In the general formula (I), R1 is hydrogen or alkyl group of C1-C5. R2 is hydrogen, hydroxyl group, alkyl group of C1-C5 or alkoxy group of C1-C5. R3 is alkyl group of C1-C5 or structure formula (i). In the structure (i), R5 is alkoxy group of C1-C5.

Abstract translation: 提供白血病治疗剂，以平行使用全反式视黄酸（ATRA）和茚并[1,2-c]异喹啉衍生物安全治疗白血病。 抗癌药包括作为活性成分的全反式维甲酸和通式（I）的茚并[1,2-c]异喹啉衍生物和药学上可允许的载体。 在通式（I）中，R 1是氢或C 1 -C 5的烷基。 R2是氢，羟基，C1-C5烷基或C1-C5的烷氧基。 R3是C1-C5的烷基或结构式（i）。 在结构（ⅰ）中，R 5为C 1 -C 5的烷氧基。